Early phase expansion CARBOGEN AMCIS launched SPRINT, a dedicated early-phase drug substance development platform, signaling an opportunity to offer rapid, scalable CDMO services for clients seeking faster progression to clinical trials.

ADC capabilities The company operates dedicated Highly Potent API facilities and a clean room for Antibody Drug Conjugates, plus a recent partnership with Celonic Group to enhance ADC development and manufacturing, presenting a strong cross-sell into biologics and targeted therapies.

Global expansion Expansion to China and Eastern Asia with ANVISA audit success indicates potential to pursue regional biologics and API programs, leveraging local regulatory and manufacturing footprints to win multi-region CRO/CDMO projects.

Regulatory credibility Recent GMP compliance certification at the Saint-Beauzire site and ongoing cGMP infrastructure underscore reliability and quality, a key differentiator for customers seeking compliant supply chains and risk mitigation.

Integrated offerings diversified services spanning drug substance, drug products development, and cholesterol and vitamin D analogs, plus CDMO leadership awards recognition, create opportunities to cross-sell integrated chemistry and formulation capabilities to large pharma and biotech clients.